Tag
This analysis reveals comparable 10-year mortality, valve durability, and hemodynamics between SAPIEN 3 transcatheter and surgical aortic valve replacement in intermediate-risk patients, underscoring TAVR’s durable benefit.
Three-year pooled data from the ALTERRA trials demonstrate that the Alterra Adaptive Prestent combined with the SAPIEN 3 THV is highly effective and safe for treating severe pulmonary regurgitation in patients with large right ventricular o
The COMPARE-TAVI 1 trial demonstrates non-inferiority of Myval transcatheter heart valves compared to SAPIEN 3 THVs at 1-year post-TAVI for a composite clinical endpoint in severe aortic stenosis patients.
